Pharminent

NICE recommends AstraZeneca lung treatment

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) is has emerged, meaning the therapy could soon be available for routine use on the NHS. The assessment covers adults whose severe COPD has not responded to other treatments.
read more http://www.pharmafile.com/news/514510/nice-recommends-astrazeneca-lung-treatment

Filed under: COPD